Invasive Markers Identified by Gene Expression Profiling in Pancreatic Cancer
Overview
Gastroenterology
Authors
Affiliations
Background: Molecular profiling has proven utility as a diagnostic and predictive tool in clinical oncology. However, a clinically relevant gene expression profile in pancreatic cancer remains elusive.
Methods: Primary and metastatic pancreatic cancer cell lines (BxPC-3 and AsPC-1), were stimulated with phorbol-12-myristate 13-acetate (PMA), a known inducer of cell invasion. Affymetrix gene expression microarray analysis was performed, comparing gene expression to unstimulated controls. Differential expression was identified using ArrayAssist, and confirmed using quantitative real-time PCR. Bioinformatic analysis was performed using Pathway Studio and GOstat. The derived gene expression was further validated in fresh frozen pancreatic tumour samples. The ability of the derived 3 gene expression markersto differentiate between pancreatic adenocarcinoma (PDAC) and other neoplasms, and its association with clinicopathological variables was examined.
Results: PMA-induced significant changes in cell line gene expression, from which distinctive 3 potential invasive markers were derived. Expression of these genes, uPA, MMP-1 and IL1-R1 was confirmed in human pancreatic tumours, and was found to differentiate PDAC from other pancreatic neoplasms. The expression of IL1-R1 in PDAC is a novel finding. We found that the expression of MMP-1 was associated with high-grade PDAC (p = 0.035, Wilcoxon rank sum).
Conclusion: We have identified three potential invasive markers, uPA, MMP-1 and IL1-R1, whose gene expression may differentiate PDAC from other pancreatic neoplasms, and potentially reflect a more invasive phenotype.
Kumar A, Buckley B, Ranson M Biomolecules. 2022; 12(2).
PMID: 35204653 PMC: 8961517. DOI: 10.3390/biom12020152.
Liu N, Zhong L, Ni G, Lin J, Xie L, Li T Onco Targets Ther. 2021; 14:4391-4406.
PMID: 34408436 PMC: 8364391. DOI: 10.2147/OTT.S309576.
Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?.
Slapak E, Duitman J, Tekin C, Bijlsma M, Spek C Biology (Basel). 2020; 9(4).
PMID: 32325664 PMC: 7235986. DOI: 10.3390/biology9040080.
Mezencev R, Matyunina L, Wagner G, McDonald J Cancer Gene Ther. 2016; 23(12):446-453.
PMID: 27910856 PMC: 5159445. DOI: 10.1038/cgt.2016.71.
Little E, Camp E, Wang C, Watson P, Watson D, Cole D Oncogenesis. 2016; 5:e182.
PMID: 26751936 PMC: 4728675. DOI: 10.1038/oncsis.2015.45.